Business Context and Reporting Period
Company: Research Alliance Corporation III (RACC)
Reporting Period: Quarterly period ended June 30, 2026 (Inception: February 19, 2026)
Entity Type: Cayman Islands exempted company; Blank check company (SPAC); Emerging Growth Company; Smaller Reporting Company.
Business Status: The Company has not commenced operations. Activities are limited to formation, the Initial Public Offering (IPO), and identifying/negotiating a business combination. On July 26, 2026 (subsequent to the period end), the Company entered into a Business Combination Agreement with OHB Pediatrics Ltd. (OHBP).
Key Financial Metrics
| Metric | Value |
|---|---|
| Total Assets | $76,307,137 |
| Cash and Cash Equivalents | $832,812 |
| Marketable Securities (Trust Account) | $75,238,468 |
| Total Liabilities | $2,305,587 |
| Deferred Underwriting Fee | $2,250,000 |
| Working Capital | $905,874 |
| Net Income (3 Months Ended June 30, 2026) | $54,050 |
| Net Loss (Inception to June 30, 2026) | $(11,199) |
| Interest Income (Trust Account) | $238,468 |
| Operating Expenses (3 Months) | $184,418 |
Material Changes and Transactions
- Initial Public Offering (IPO): Consummated on May 21, 2026. Sold 7,500,000 Class A ordinary shares at $10.00 per share, generating gross proceeds of $75,000,000. Offering costs totaled $3,762,251 (including $2,250,000 deferred underwriting commissions).
- Private Placement: Simultaneously with the IPO, sold 275,000 Private Placement Shares to the Sponsor for $2,750,000.
- Trust Account: $75,000,000 deposited into the Trust Account at IPO closing. As of June 30, 2026, the balance grew to $75,238,468 due to interest earned on U.S. government securities.
- Repayment of Sponsor Note: Repaid a $300,000 promissory note from the Sponsor upon IPO closing.
- Subsequent Event: Entered into a Business Combination Agreement with OHB Pediatrics Ltd. on July 26, 2026, including a $55,000,000 PIPE financing and a $75,000,000 backstop agreement.
Outlook, Risks, and Contingencies
- Going Concern: The filing states that the Company lacks the financial resources to sustain operations for a reasonable period (one year) without completing a business combination or raising additional capital, raising substantial doubt about its ability to continue as a going concern.
- Business Combination Timeline: The Company must complete a business combination within 24 months of the IPO (by May 2028) or liquidate. The proposed OHBP combination is expected to close in the second half of 2026.
- Redemption Rights: Public shareholders have the right to redeem their shares for a pro rata portion of the Trust Account (approx. $10.00 per share plus interest) upon the completion of a business combination.
- Internal Controls: Management identified a material weakness in internal control over financial reporting regarding the accounting for accounts payable and accrued expenses. A remediation plan is in progress.
- Contingencies: The deferred underwriting fee of $2,250,000 is payable only upon the successful completion of a business combination. The Sponsor has agreed to indemnify the Trust Account against certain third-party claims.
Investor Verification Checklist
- Business Combination Status: Verify the progress and closing conditions of the OHB Pediatrics Ltd. merger announced July 26, 2026.
- Redemption Levels: Monitor shareholder redemption rates, which could impact the cash available for the transaction and the need for the $75,000,000 backstop.
- Internal Control Remediation: Confirm the completion of the remediation plan for the material weakness in financial reporting controls.
- Liquidity Sufficiency: Assess whether the $832,812 in working capital outside the Trust Account is sufficient to fund operations until the merger closes or liquidation occurs.
- PIPE and Backstop Execution: Verify the finalization of the $55,000,000 PIPE financing and the terms of the backstop agreement.